This study focuses on patients* who received basiliximab as induction therapy during organ transplantation from 2016 to 2020 (corresponding cases in nationwide survey conducted by the Japanese Society for Transplantation from 2016 to 2020). *Patients include domestic cases in which basiliximab was administered before 2016.
Conditions
Interventions
None listed
Sponsors
Nagasaki University Hospital
The Japan Society for Transplantation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Adults* and pediatric patients in whom patients or his/her legal guardians gave consented to the research approved at the Ethics Committee by informed consent or are guaranteed the opportunity to refuse the data of use by opt out. 2.Adult and pediatric transplant patients who received basiliximab as induction therapy from January 1st,2016 to December 31st ,2020 ( including patients who received transplantation simultaneously more than one (liver, heart, lung, small intestine, pancreas and islets)) However, patients with transplantation for small intestine before 2016 are also acceptable. In this study, the pharmaceutical definition of adult is 15 years of age or older.
Exclusion criteria
Exclusion criteria: Patients who received simultaneously organ transplantation of pancreatic and kidney
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events in patients with any transplanted organ during the 6 months after transplantation | — |
Countries
Japan
Contacts
Public ContactNarumi Tashiro
EPS Corporation Clinical Research Center Real World Evidence Business Headquarters
Outcome results
None listed